JUNE 9, 2026 AT 02:03 PM

J&J (JNJ) says they are well on track to reach the upper end of its 5-7% 5-year growth target despite Stelara loss of exclusivity

Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.

Open Dashboard

#JOHNSON & JOHNSON#JNJ.US#EQUITIES#EU SESSION#US SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#JNJ#US EQUITIES